Immunologic Signatures of SARS-CoV-2 Vaccination and Disease
- Funded by National Institutes of Health (NIH)
- Total publications:8 publications
Grant number: 1U01CA260476-01
Grant search
Key facts
Disease
COVID-19Start & end year
20202022Known Financial Commitments (USD)
$1,477,970Funder
National Institutes of Health (NIH)Principal Investigator
Dan H BarouchResearch Location
United States of AmericaLead Research Institution
Beth Israel Deaconess Medical CenterResearch Priority Alignment
N/A
Research Category
Pathogen: natural history, transmission and diagnostics
Research Subcategory
Immunity
Special Interest Tags
N/A
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified
Abstract
Abstract: The development of a SARS-CoV-2 vaccine may be critical to ending the COVID-19 pandemic. However, acritical gap in knowledge is the lack of understanding of correlates of SARS-CoV-2 immunity in humans.Our preliminary data suggest that antibodies correlate with protection following vaccination in nonhumanprimates and that unique antibody functional profiles appear to predict disease outcome in natural infection inhumans. Our data also point to a converging antibody profile, including both the antigen-binding domain drivingneutralization and Fc-mediated effector functions driving protective immunity. Another gap in knowledge is theunknown durability of protective immunity following SARS-CoV-2 infection and vaccination in humans.Our preliminary data suggest that antibody titers may wane quickly following SARS-CoV-2 infection in humans,but larger studies and longer follow-up are needed to define the kinetics of antibody responses in convalescentindividuals. Moreover, the durability of vaccine-elicited antibody responses remains to be determined.We hypothesize that both convalescent and vaccinated humans will develop the functional antibodysignature that correlates with vaccine protection against SARS-CoV-2 challenge in rhesus macaques.We further hypothesize that vaccination will induce antibodies with greater durability than those inducedby natural infection and that an immunologic correlate of durability can be defined.Specific Aim 1. Define the antibody profiles following SARS-CoV-2 infection or vaccination that correlatewith protection. We will dissect the functional antibody responses elicited in SARS-CoV-2 infected individualsand in SARS-CoV-2 vaccinated individuals to provide insight into correlates of protection.Specific Aim 2. Define the immunologic correlates of durability of SARS-CoV-2 antibody responsesfollowing infection or vaccination. We will compare the durability of antibody responses induced in SARS-CoV-2 infected and vaccinated individuals, and we will define an immunologic correlate of durability.
Publicationslinked via Europe PMC
Last Updated:2 days ago
View all publications at Europe PMC